181 related articles for article (PubMed ID: 20370689)
1. In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin.
González A; Alvarez-García V; Martínez-Campa C; Mediavilla MD; Alonso-González C; Sánchez-Barceló EJ; Cos S
Curr Cancer Drug Targets; 2010 May; 10(3):279-86. PubMed ID: 20370689
[TBL] [Abstract][Full Text] [Related]
2. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity.
Cos S; González A; Güezmes A; Mediavilla MD; Martínez-Campa C; Alonso-González C; Sánchez-Barceló EJ
Int J Cancer; 2006 Jan; 118(2):274-8. PubMed ID: 16080194
[TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE.
Purohit A; Woo LW; Potter BV; Reed MJ
Cancer Res; 2000 Jul; 60(13):3394-6. PubMed ID: 10910045
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats.
Luo S; Stojanovic M; Labrie C; Labrie F
Int J Cancer; 1997 Nov; 73(4):580-6. PubMed ID: 9389575
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives.
Selcer KW; Jagannathan S; Rhodes ME; Li PK
J Steroid Biochem Mol Biol; 1996 Sep; 59(1):83-91. PubMed ID: 9009241
[TBL] [Abstract][Full Text] [Related]
6. Effect of estrone on the growth of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in the rat: a model of postmenopausal breast cancer.
Li S; Martel C; Dauvois S; Bélanger A; Labrie F
Endocrinology; 1994 Mar; 134(3):1352-7. PubMed ID: 8119175
[TBL] [Abstract][Full Text] [Related]
7. Evidence of in situ estrogen synthesis in nitrosomethylurea-induced rat mammary tumors via the enzyme estrone sulfatase.
Masamura S; Santner SJ; Santen RJ
J Steroid Biochem Mol Biol; 1996 Jul; 58(4):425-9. PubMed ID: 8903427
[TBL] [Abstract][Full Text] [Related]
8. Development of novel steroid sulfatase inhibitors; II. TZS-8478 potently inhibits the growth of breast tumors in postmenopausal breast cancer model rats.
Saito T; Kinoshita S; Fujii T; Bandoh K; Fuse S; Yamauchi Y; Koizumi N; Horiuchi T
J Steroid Biochem Mol Biol; 2004 Feb; 88(2):167-73. PubMed ID: 15084348
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of medroxyprogesterone acetate (MPA) and the pure antiestrogen EM-219 on estrone (E1)-stimulated growth of dimethylbenz(a)anthracene (DMBA)-induced mammary carcinoma in the rat.
Li S; Lévesque C; Geng CS; Yan X; Labrie F
Breast Cancer Res Treat; 1995 May; 34(2):147-59. PubMed ID: 7647332
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic control of estrogen production in human breast cancer: relative significance of aromatase versus sulfatase pathways.
Santen RJ; Leszczynski D; Tilson-Mallet N; Feil PD; Wright C; Manni A; Santner SJ
Ann N Y Acad Sci; 1986; 464():126-37. PubMed ID: 3524346
[TBL] [Abstract][Full Text] [Related]
11. Estrogenicity, antiestrogenicity and estrone sulfatase inhibition of estrone-3-amine and estrone-3-thiol.
Selcer KW; Li PK
J Steroid Biochem Mol Biol; 1995 Mar; 52(3):281-6. PubMed ID: 7696150
[TBL] [Abstract][Full Text] [Related]
12. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.
Santner SJ; Feil PD; Santen RJ
J Clin Endocrinol Metab; 1984 Jul; 59(1):29-33. PubMed ID: 6725522
[TBL] [Abstract][Full Text] [Related]
13. Development of potent non-estrogenic estrone sulfatase inhibitors.
Li PK; Chu GH; Guo JP; Peters A; Selcer KW
Steroids; 1998; 63(7-8):425-32. PubMed ID: 9654650
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase by antiestrogens.
Santner SJ; Santen RJ
J Steroid Biochem Mol Biol; 1993 May; 45(5):383-90. PubMed ID: 8388710
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of melatonin on sulfatase and 17beta-hydroxysteroid dehydrogenase activity and expression in glioma cells.
González A; Martínez-Campa C; Mediavilla MD; Alonso-González C; Alvarez-García V; Sánchez-Barceló EJ; Cos S
Oncol Rep; 2010 Apr; 23(4):1173-8. PubMed ID: 20204307
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
17. Steroidal oxathiazine inhibitors of estrone sulfatase.
Peters RH; Chao WR; Sato B; Shigeno K; Zaveri NT; Tanabe M
Steroids; 2003 Jan; 68(1):97-110. PubMed ID: 12475726
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (p-O-sulfamoyl)-N-alkanoyl tyramines.
Selcer KW; Hegde PV; Li PK
Cancer Res; 1997 Feb; 57(4):702-7. PubMed ID: 9044848
[TBL] [Abstract][Full Text] [Related]
19. Sulfamoyloxy-substituted 2-phenylindoles: antiestrogen-based inhibitors of the steroid sulfatase in human breast cancer cells.
Golob T; Liebl R; von Angerer E
Bioorg Med Chem; 2002 Dec; 10(12):3941-53. PubMed ID: 12413846
[TBL] [Abstract][Full Text] [Related]
20. The mechanisms of antitumor effects of luteinizing hormone-releasing hormone agonist (buserelin) in 7, 12-dimethylbenz(a)anthracene-induced rat mammary cancer.
Koibuchi Y; Sugamata N; Iino Y; Yokoe T; Andoh T; Maemura M; Takei H; Horiguchi J; Matsumoto H; Morishita Y
Int J Mol Med; 1999 Aug; 4(2):145-8. PubMed ID: 10402480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
